| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | ZETAGEN THERAPEUTICS INC | 841 E FAYETTE ST | SYRACUSE | NY | 13210-1530 | ONONDAGA | USA | R44CA221553 | Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases | 000 | 3 | NIH | 3/12/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,235,336 ) |
| | 2022 | 2022 | ZETAGEN THERAPEUTICS INC | 841 E FAYETTE ST | SYRACUSE | NY | 13210-1530 | ONONDAGA | USA | R44CA221553 | Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases | 001 | 3 | NIH | 7/27/2022 | $985,336 |
| | 2022 | 2022 | ZETAGEN THERAPEUTICS INC | 841 E FAYETTE ST | SYRACUSE | NY | 13210-1530 | ONONDAGA | USA | R44CA221553 | Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases | 000 | 2 | NIH | 6/9/2022 | $250,000 |
|
| Issue Date FY: 2021 ( Subtotal = $1,014,441 ) |
| | 2021 | 2021 | ZETAGEN THERAPEUTICS, INC. | 841 E FAYETTE ST STE 1100 | SYRACUSE | NY | 13210-1536 | ONONDAGA | USA | R44CA221553 | Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases | 000 | 2 | NIH | 8/15/2021 | $1,014,441 |
| | 2021 | 2019 | ZETAGEN THERAPEUTICS, INC. | 841 E FAYETTE ST STE 1100 | SYRACUSE | NY | 13210-1536 | ONONDAGA | USA | R43AR075483 | Validation of a novel, small molecule-based osteoinductive lumbar fusion implant | 000 | 1 | NIH | 11/9/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = -$1,750 ) |
| | 2020 | 2019 | ZETAGEN THERAPEUTICS, INC. | 841 E FAYETTE ST STE 1600 | SYRACUSE | NY | 13210-1530 | ONONDAGA | USA | R43CA221553 | Validation of a novel, adjuvant implant for post-metastatic skeletal lesions | 001 | 1 | NIH | 11/11/2019 | $0 |
| | 2020 | 2019 | ZETAGEN THERAPEUTICS, INC. | 841 E FAYETTE ST STE 1600 | SYRACUSE | NY | 13210-1530 | ONONDAGA | USA | R43CA221553 | Validation of a novel, adjuvant implant for post-metastatic skeletal lesions | 002 | 1 | NIH | 5/19/2020 | -$1,750 |
| | 2020 | 2018 | ZETAGEN THERAPEUTICS, INC. | 841 E FAYETTE ST STE 1600 | SYRACUSE | NY | 13210-1530 | ONONDAGA | USA | R43CA221553 | Validation of a novel, adjuvant implant for post-metastatic skeletal lesions | 000 | 1 | NIH | 11/11/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $226,554 ) |
| | 2019 | 2019 | FUSOLOGICS LLC | 233 OARLOCK CIR | EAST SYRACUSE | NY | 13057-3120 | ONONDAGA | USA | R43CA221553 | Validation of a novel, adjuvant implant for post-metastatic skeletal lesions | 001 | 1 | NIH | 8/22/2019 | $1,750 |
| | 2019 | 2019 | ZETAGEN THERAPEUTICS, INC. | 841 E FAYETTE ST STE 1600 | SYRACUSE | NY | 13210-1530 | ONONDAGA | USA | R43AR075483 | Validation of a novel, small molecule-based osteoinductive lumbar fusion implant | 000 | 1 | NIH | 9/11/2019 | $224,804 |
| | 2019 | 2018 | FUSOLOGICS LLC | 233 OARLOCK CIR | EAST SYRACUSE | NY | 13057-3120 | ONONDAGA | USA | R43CA221553 | Validation of a novel, adjuvant implant for post-metastatic skeletal lesions | 000 | 1 | NIH | 12/20/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $299,958 ) |
| | 2018 | 2018 | FUSOLOGICS LLC | 233 OARLOCK CIR | EAST SYRACUSE | NY | 13057-3120 | ONONDAGA | USA | R43CA221553 | Validation of a novel, adjuvant implant for post-metastatic skeletal lesions | 000 | 1 | NIH | 9/5/2018 | $299,958 |
|
|
